{"gene":"FHL1","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2008,"finding":"FHL1 forms a complex within the cardiomyocyte sarcomere that senses biomechanical stress via the N2B stretch sensor domain of titin and initiates changes in titin- and MAPK-mediated responses important for sarcomere extensibility and intracellular signaling. Fhl1-deficient mice show blunted hypertrophic response to pressure overload, and Fhl1 deficiency prevents cardiomyopathy in Gq transgenic mice, placing FHL1 downstream of Gq signaling in pathological hypertrophy.","method":"Fhl1 knockout mice + transverse aortic constriction, Gq transgenic mouse epistasis, co-immunoprecipitation with titin N2B domain and MAPK components","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic epistasis (two independent mouse models), co-immunoprecipitation identifying complex members, loss-of-function with defined molecular and cardiac phenotype","pmids":["19033658"],"is_preprint":false},{"year":2010,"finding":"FHL1 binds to the calcineurin-regulated transcription factor NFATc1, enhancing NFATc1 transcriptional activity. FHL1 overexpression promotes skeletal muscle hypertrophy and an oxidative fiber-type switch via this calcineurin/NFATc1 signaling axis; RBM-mutant FHL1 sequesters NFATc1 in aggregates, reducing NFAT nuclear translocation and transcriptional activity.","method":"Co-immunoprecipitation of FHL1 with NFATc1; calcineurin inhibitor rescue of FHL1-induced hypertrophic myotube phenotype in C2C12 cells; NFATc1 localization studies; FHL1 transgenic mice","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, calcineurin inhibitor epistasis rescue, in vivo transgenic model, multiple orthogonal methods in single study replicated across cell and animal models","pmids":["19075112"],"is_preprint":false},{"year":1999,"finding":"SLIM1 (FHL1) localizes to focal adhesions and actin filaments in COS-7 cells. The isoform SLIMMER (FHL1B/KyoT3) localizes to the nucleus of myoblasts via a bipartite nuclear localization signal and is exported to the cytoplasm of myotubes via a leucine-rich nuclear export sequence. These distinct localizations suggest separate roles in focal adhesion signaling versus nuclear-cytoplasmic communication.","method":"GFP fusion protein live-cell imaging in COS-7 cells and Sol8 myoblasts/myotubes; truncation mutant analysis of NLS and NES sequences; immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct GFP localization with functional domain dissection by multiple truncation mutants; subcellular localization tied to isoform-specific sequences","pmids":["10480922"],"is_preprint":false},{"year":2003,"finding":"SLIM1/FHL1 overexpression in differentiating skeletal myocytes induces alpha5beta1-integrin-dependent hyperelongation; in undifferentiated reserve cells it induces integrin-mediated cytoplasmic branching. These effects were blocked by poly-L-lysine plating or peptide blockade of alpha5beta1-integrin ligand binding, establishing a specific dependence on alpha5beta1-integrin signaling.","method":"SLIM1 overexpression in Sol8/C2C12 cells; peptide blockade of alpha5beta1-integrin; poly-L-lysine substrate control; cell morphology analysis","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function peptide blockade plus overexpression, single lab, two orthogonal blocking approaches confirming integrin dependence","pmids":["12917103"],"is_preprint":false},{"year":2008,"finding":"FHL1 is identified as the protein mutated in reducing body myopathy (RBM). Mutant FHL1 expressed in COS-7 and C2C12 cells forms aggresome-like inclusions that incorporate both mutant and wild-type FHL1 and trap other proteins in a dominant-negative manner.","method":"Laser microdissection of inclusions + nanoflow LC-MS/MS proteomics; transfection of mutant FHL1 into COS-7 and C2C12 cells; immunofluorescence imaging of aggregates","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — novel proteomic identification combined with cell transfection demonstrating dominant-negative aggregate formation, multiple cell types tested","pmids":["18274675"],"is_preprint":false},{"year":2009,"finding":"FHL1 interacts directly with the hypervariable domain (HVD) of chikungunya virus nsP3 protein, and this interaction is essential for CHIKV RNA replication. Cells lacking FHL1 are resistant to CHIKV infection; FHL1 expression in non-expressing cells promotes CHIKV infection.","method":"FHL1 knockout/knockdown cells, direct binding assay, viral RNA replication assay, FHL1 expression rescue in non-expressing cells, Fhl1-knockout mice infected with CHIKV","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding established, loss-of-function in both cell lines and KO mice, rescue by re-expression, multiple viral strains tested across multiple labs","pmids":["31554973"],"is_preprint":false},{"year":2020,"finding":"NMR structural studies revealed that FHL1 binds CHIKV nsP3 HVD predominantly via its LIM1 domain, with the binding site overlapping that of CD2AP. FHL1 and CD2AP have additive proviral effects on CHIKV replication efficiency.","method":"NMR-based structural mapping of FHL1-HVD interaction; LIM domain truncation analysis; CHIKV replication assays in FHL1 KO cell lines; competition with CD2AP","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural mapping with domain-level resolution combined with functional viral replication assays; single lab but orthogonal structural and biological methods","pmids":["33055253"],"is_preprint":false},{"year":2001,"finding":"FHL1C (KyoT2 homolog) localizes to both nucleus and cytoplasm; its C-terminal RBP-J binding region is required for this distribution. FHL1B localizes predominantly to the nucleus via its C-terminal bipartite NLS and is brain-specifically expressed.","method":"Immunoblot with isoform-specific antibodies; subcellular fractionation; transfection of tagged isoforms; RT-PCR tissue distribution","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — immunoblot and transfection-based localization; single lab, multiple isoforms characterized with antibody validation","pmids":["11400158"],"is_preprint":false},{"year":2008,"finding":"KyoT3 (FHL1 isoform) localizes preferentially to the nucleus, interacts with RBP-J via co-immunoprecipitation, and represses RBP-J-dependent transactivation activated by both Notch intracellular domain and EBV nuclear antigen 2.","method":"EGFP fusion protein localization; co-immunoprecipitation of KyoT3 with RBP-J; luciferase reporter assay for RBP-J-dependent promoter","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional reporter assay, single lab, two orthogonal methods confirming RBP-J interaction and transcriptional repression","pmids":["18760388"],"is_preprint":false},{"year":2006,"finding":"Src phosphorylates Cas to suppress FHL1 expression (via promoter methylation), and suppression of FHL1 is required for Src to promote tumor cell anchorage-independent growth and migration, placing FHL1 downstream of the Src-Cas signaling axis as a tumor suppressor.","method":"Gene expression analysis of >14,000 genes; Src and Cas expression/inhibition experiments; anchorage-independent growth and migration assays in tumor cells normalized by non-transformed cell contact","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via Src/Cas manipulation with defined functional phenotype (anchorage-independent growth, migration); single lab","pmids":["16452211"],"is_preprint":false},{"year":2008,"finding":"Src promotes FHL1 promoter methylation (via Cas) to suppress FHL1 expression independently of MAPK activity. FHL1 in turn induces Sdpr expression in Src-transformed cells. FHL1 and Sdpr are coordinately suppressed in breast, kidney, and prostate tumors.","method":"DNA bisulfite modification and sequencing; MAPK inhibitor treatment; gene expression arrays; immunohistochemistry of tumor vs. normal tissue","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — methylation assay plus MAPK inhibitor epistasis plus gene expression in primary tumors; single lab, multiple orthogonal methods","pmids":["18422756"],"is_preprint":false},{"year":2018,"finding":"Src phosphorylates FHL1 at Y149 and Y272, causing phosphorylated FHL1 to translocate to the nucleus where it binds the transcription factor BCLAF1 and promotes tumor cell growth. Kindlin-2 interacts with FHL1 at focal adhesions and competes with Src for FHL1 binding, suppressing Src-mediated FHL1 phosphorylation.","method":"In vitro Src kinase assay; site-directed mutagenesis of Y149 and Y272; co-immunoprecipitation of FHL1 with BCLAF1 and Kindlin-2; subcellular fractionation; tumor cell proliferation assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — site-directed mutagenesis of phosphorylation sites combined with kinase assay, Co-IP of binding partners, subcellular localization shift, and functional proliferation assay; multiple orthogonal methods","pmids":["29434030"],"is_preprint":false},{"year":2011,"finding":"FHL1 physically interacts with estrogen receptors (ERs), specifically binding the activation function-1 (AF-1) domain of ER. This interaction is required for FHL1 repression of estrogen-responsive gene transcription; FHL1 affects ER recruitment to estrogen-responsive promoters.","method":"Co-immunoprecipitation; chromatin immunoprecipitation (ChIP); luciferase reporter assays; FHL1 siRNA knockdown; overexpression in breast cancer cells","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying AF-1 binding domain, ChIP showing ER promoter recruitment changes, and siRNA rescue; single lab, multiple orthogonal methods","pmids":["19840196"],"is_preprint":false},{"year":2009,"finding":"FHL1 interacts with RIP140 (receptor interacting protein of 140 kDa) in vitro and in mammalian cells; estrogen enhances this interaction. All domains of FHL1 are required for RIP140 binding. FHL1 enhances RIP140 repression of estrogen signaling and synergistically inhibits transcription of the estrogen-responsive gene pS2.","method":"Yeast two-hybrid screening; co-immunoprecipitation in mammalian cells; luciferase reporter assay; FHL1 siRNA knockdown; FHL1 domain deletion mutants","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP in mammalian cells plus functional reporter assay; single lab, multiple orthogonal methods","pmids":["19401155"],"is_preprint":false},{"year":2011,"finding":"FHL1 exists as part of a protein complex that includes PDLIM1, gelsolin (GSN), and ACTN1 (alpha-actinin 1), as identified by tandem affinity purification from HEK-293 cells confirmed by immunoprecipitation from mouse heart ventricles and 3D fluorescence microscopy in adult cardiomyocytes.","method":"Tandem affinity purification from HEK-293 cells; LC-MS identification of interactors; reciprocal immunoprecipitation from mouse heart ventricles; 3D fluorescence microscopy","journal":"Molecular bioSystems","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity purification-MS plus reciprocal Co-IP in native cardiac tissue; single lab, two orthogonal methods with biological validation","pmids":["21246116"],"is_preprint":false},{"year":2013,"finding":"Loss of FHL1 in mice leads to an age-dependent skeletal muscle myopathy with myofibrillar and intermyofibrillar disorganization, impaired oxidative capacity, and increased autophagic activity. Re-expression of the FHL1A isoform specifically rescues early muscle fiber differentiation and maturation defects in primary FHL1-null myoblasts, establishing FHL1A as necessary for proper muscle fiber differentiation.","method":"FHL1-null mice; histological, ultrastructural (EM), and functional muscle analyses; primary myoblast isolation and re-expression of FHL1A isoform; longitudinal survival study","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete KO mouse model with longitudinal analysis, rescue by isoform-specific re-expression, multiple orthogonal histological/functional readouts","pmids":["23975679"],"is_preprint":false},{"year":2005,"finding":"Rho/CRIK signaling suppresses keratinocyte differentiation through up-regulation of KyoT1/2 (FHL1) expression. Elevated KyoT1/2 expression suppresses differentiation similarly to activated Rho and CRIK, placing FHL1 downstream of the Rho-CRIK pathway in keratinocyte self-renewal/differentiation control.","method":"RhoA and CRIK overexpression/inhibition in keratinocytes; gene expression analysis; KyoT1/2 overexpression in keratinocytes with differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis placing FHL1 downstream of Rho/CRIK with defined differentiation phenotype; single lab, multiple genetic manipulations","pmids":["16061799"],"is_preprint":false},{"year":2015,"finding":"FHL1 activates myostatin signaling; FHL1 increases myostatin activity on a SMAD reporter and increases myostatin-dependent myotube wasting. Co-expression of FHL1 and myostatin in mice reduced fiber diameter to a greater extent than myostatin alone, demonstrating that FHL1 can promote muscle atrophy by potentiating TGFβ/myostatin-SMAD signaling.","method":"SMAD luciferase reporter assay; myotube wasting assay; in vivo electroporation of FHL1 and myostatin into mouse muscle; fiber diameter measurement","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus in vivo co-expression epistasis; single lab, two orthogonal methods","pmids":["26504741"],"is_preprint":false},{"year":2009,"finding":"SLIMMER (FHL1B/KyoT3) interacts with the proapoptotic protein Siva-1 via yeast two-hybrid, direct binding, and GST pulldown from skeletal muscle lysates. SLIMMER and Siva-1 co-localize in the nucleus of C2C12 myoblasts and redistribute to the cytoplasm upon differentiation, and to the Z-line in mature skeletal muscle. SLIMMER delays Siva-1-dependent apoptosis in C2C12 myoblasts.","method":"Yeast two-hybrid screen; direct binding assay; GST pulldown from muscle lysates; co-localization by immunofluorescence; apoptosis assay in C2C12 myoblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — three orthogonal protein interaction methods (yeast two-hybrid, direct binding, GST pulldown) plus co-localization and functional apoptosis assay; single lab but rigorous multi-method approach","pmids":["19643733"],"is_preprint":false},{"year":2013,"finding":"FHL1 overexpression promotes NFATc1 activation of the utrophin promoter and increases sarcolemmal expression of utrophin in mdx mice, directing assembly of a substitute utrophin-glycoprotein complex, thereby ameliorating dystrophic pathology. This defines a novel FHL1-NFATc1-utrophin signaling axis.","method":"FHL1 transgenic/mdx double-mutant mice; utrophin promoter-luciferase reporter assay; sarcolemmal membrane stability assays; immunohistochemistry; muscle function tests","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo double-mutant mouse model, reporter assay defining FHL1-NFATc1-utrophin pathway, multiple functional and molecular readouts; single lab but comprehensive approach","pmids":["24087791"],"is_preprint":false},{"year":2008,"finding":"FHL1 expression in pulmonary artery smooth muscle cells is upregulated in pulmonary hypertension. FHL1 knockdown suppresses, while FHL1 overexpression increases, PASMC migration and proliferation. Co-immunoprecipitation identified Talin1 as a new FHL1-interacting partner in this context.","method":"2D-PAGE proteomics; siRNA knockdown; adenoviral overexpression; co-immunoprecipitation with Talin1; migration and proliferation assays in primary human PASMCs","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying Talin1 interaction, siRNA/overexpression functional assays; single lab, multiple orthogonal methods","pmids":["18725486"],"is_preprint":false},{"year":2008,"finding":"RBM and SPM FHL1 mutations affecting conserved zinc-coordinating residues in the LIM2 domain lead to protein aggregation. Molecular dynamics simulations of LIM2 mutations showed increased nonpolar solvent-accessible surface area without major structural distortion or disruption of zinc binding, suggesting the mutations increase propensity to aggregate.","method":"Transfection of mutant FHL1 into C2C12 cells (aggregate formation); molecular dynamics simulations of LIM2 domain mutations; immunohistochemistry of muscle biopsies","journal":"Journal of the neurological sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — computational structural modeling plus cell transfection aggregate assay; single lab, limited experimental validation of MD predictions","pmids":["20633900"],"is_preprint":false},{"year":2014,"finding":"RBM, SPM, and XMPMA FHL1 mutants expressed in C2C12 cells form aggregates positive for the reducing body stain Menadione-NBT and impair myoblast differentiation. HCM and EDMD FHL1 mutants generally show reduced protein expression instead of aggregation. SPM and XMPMA mutant-induced impaired myotube formation is partially rescued by constitutively active NFATc1, confirming FHL1 acts through NFATc1 signaling in myoblast differentiation.","method":"Expression of disease mutants in C2C12 cells; Menadione-NBT staining; myotube formation assay; constitutively active NFATc1 rescue experiment; immunofluorescence","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple disease mutants with defined cellular phenotypes; NFATc1 rescue epistasis; single lab, multiple orthogonal readouts","pmids":["24634512"],"is_preprint":false},{"year":2016,"finding":"FHL1B isoform localizes to the nuclear envelope of primary human myoblasts, co-localizing with but independently of lamin A/C and emerin. FHL1B protein expression is markedly reduced during myoblast differentiation. FHL1B is elevated in myoblasts from FHL1-related EDMD patients (where the mutation only affects FHL1A) and from LMNA-related EDMD patients.","method":"Immunofluorescence of primary human myoblasts; western blotting; subcellular fractionation; analysis of EDMD patient myoblasts","journal":"Journal of neuromuscular diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence in primary cells confirmed by western blot; single lab, patient-derived cell validation","pmids":["27911330"],"is_preprint":false},{"year":2019,"finding":"FHL1 regulates myoblast differentiation through interaction with LC3; FHL1 and LC3 interact by immunoprecipitation and co-immunofluorescence to regulate autophagosome formation. FHL1 silencing inhibits ATG5 and ATG7 expression, promotes apoptosis (increased cleaved caspase-3 and PARP), and FHL1 rescues skeletal muscle atrophy by regulating Atrogin-1 and MuRF1 expression.","method":"FHL1 siRNA knockdown and overexpression in chicken myoblasts; immunoprecipitation of FHL1 with LC3; immunofluorescence co-localization; western blot for autophagy and differentiation markers","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing FHL1-LC3 interaction plus functional knockdown/overexpression with defined molecular and morphological phenotypes; single lab","pmids":["31637727"],"is_preprint":false},{"year":2022,"finding":"FHL1 promotes blastocyst-epithelial adhesion by increasing HOXA10 protein stability and activating HOXA10 transcriptional activity via enhanced deacetylation of HOXA10 through increased HOXA10-SIRT2 binding. FHL1 does not regulate HOXA10 mRNA but acts post-translationally; SIRT2-specific inhibitors block this effect. FHL1 also activates the downstream β3 integrin/FAK pathway.","method":"FHL1 overexpression/knockdown in endometrial epithelial cells; mouse uterine FHL1 knockdown inhibiting embryo implantation; co-immunoprecipitation of HOXA10-SIRT2; HOXA10 protein stability assays; SIRT2 inhibitor treatment; β3 integrin/FAK pathway analysis","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying HOXA10-SIRT2 interaction mediated by FHL1, in vivo mouse implantation model, pharmacological inhibitor validation; single lab","pmids":["36418297"],"is_preprint":false},{"year":2015,"finding":"FHL1 expression is induced by Wnt signaling (β-catenin or LiCl) through TCF/LEF binding sites in the Fhl1 promoter; mutation of two TCF/LEF consensus sites significantly decreases promoter activity. Fhl1 knockdown in C2C12 cells reduces myotube formation, establishing Fhl1 as a downstream effector of Wnt signaling in myogenesis.","method":"Fhl1 promoter-luciferase reporter assay; TCF/LEF site mutagenesis; β-catenin and LiCl treatment; Fhl1 siRNA knockdown; myotube formation assay in C2C12 cells","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis identifying TCF/LEF regulatory elements plus siRNA functional assay; single lab, multiple orthogonal methods","pmids":["25676585"],"is_preprint":false},{"year":2023,"finding":"FHL1 is required for CHIKV and ONNV (but not RRV or MAYV) pathogenesis in vivo; FHL1-/- mice infected with CHIKV or ONNV show reduced arthritis, myositis, and immune infiltrates. Pull-down assays confirmed CHIKV and ONNV nsP3 interact with FHL1 while RRV and MAYV nsP3 do not. A CHIKV mutant unable to bind FHL1 (CHIKV-ΔFHL1) was avirulent and conferred protection against subsequent CHIKV/ONNV challenge.","method":"FHL1-/- mouse generation; in vivo infection with multiple alphaviruses; pull-down assays of nsP3 with FHL1; engineering of CHIKV-ΔFHL1 mutant; challenge experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO mouse model with multiple viral strains, direct pull-down confirming virus-specific binding, engineered viral mutant with in vivo functional validation; replicated across CHIKV and ONNV","pmids":["37884534"],"is_preprint":false},{"year":2023,"finding":"The deubiquitinase OTUD1 deubiquitinates and stabilizes FHL1 protein, inhibiting lung adenocarcinoma progression. OTUD1 was identified as a FHL1-interacting protein by IP-MS, and co-IP confirmed their interaction; OTUD1 overexpression increased FHL1 protein levels without affecting FHL1 transcription.","method":"IP-MS identification of OTUD1 as FHL1 interactor; co-immunoprecipitation; western blot for FHL1 protein levels with OTUD1 manipulation; in vitro and in vivo tumor growth assays","journal":"Cellular oncology (Dordrecht, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP-MS plus reciprocal Co-IP identifying deubiquitination interaction; functional protein stability assay; single lab","pmids":["36929488"],"is_preprint":false},{"year":2008,"finding":"HOXD13 directly regulates FHL1 expression in rat embryo limb development. Luciferase assay and EMSA identified a novel FHL1 promoter region that directly interacts with HOXD13. Chromatin immunoprecipitation confirmed that endogenous HOXD13 interacts with this FHL1 promoter region in the developing limb.","method":"Luciferase reporter assay; EMSA; ChIP from developing rat limb; immunofluorescence staining of embryonic tissue","journal":"Cytogenetic and genome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP from native tissue confirming endogenous HOXD13-FHL1 promoter interaction, supported by EMSA and luciferase assay; single lab, multiple orthogonal methods","pmids":["18758158"],"is_preprint":false},{"year":2015,"finding":"FHL1 is a target of the cytotoxic protease granzyme B, indicating that generation of FHL1 fragments may initiate FHL1 autoimmunity in inflammatory myopathies (IIM). Anti-FHL1 autoantibodies were detected in 25% of IIM patients and were predictive for muscle atrophy and vasculitis.","method":"Granzyme B cleavage assay of FHL1; ELISA detection of anti-FHL1 autoantibodies in patient serum; immunization of myositis-prone mice with FHL1","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical granzyme B cleavage assay plus in vivo immunization model demonstrating pathogenic role; single lab","pmids":["26551678"],"is_preprint":false},{"year":2014,"finding":"5'RNA-Seq revealed that HCM induces altered transcriptional start-site usage of Fhl1, producing a distinct protein isoform in stressed myocytes. Genetic ablation of Fhl1 in HCM mice was deleterious, demonstrating that the stress-induced Fhl1 transcriptional change is salutary. This conserved response was also found in humans with genetic or acquired cardiomyopathies.","method":"5'RNA-Seq for genome-wide start-site usage; Fhl1 genetic ablation in HCM mouse model; isoform-specific protein detection; analysis of human HCM samples","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel RNA-seq methodology with genetic KO epistasis in HCM model; replicated in human samples; single lab","pmids":["24509080"],"is_preprint":false},{"year":2020,"finding":"FHL1-/- mice subjected to left ventricular pressure overload showed a blunted hypertrophic response (confirming the published role of FHL1 in LV hypertrophy), but the same FHL1 deficiency did not diminish right ventricular hypertrophy, hypertrophic signaling, or dysfunction following pulmonary arterial banding, demonstrating that FHL1-mediated hypertrophic signaling is ventricle-specific.","method":"FHL1-/- mice; pulmonary arterial banding for RV pressure overload; echocardiography; gene expression analysis; comparison with transverse aortic constriction LV model","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse model with two pressure overload models (LV vs RV) as internal comparison; single lab; negative finding for RV is mechanistically informative","pmids":["31980934"],"is_preprint":false}],"current_model":"FHL1 is a multi-isoform LIM domain scaffold protein predominantly expressed in skeletal and cardiac muscle that: (1) forms a sarcomeric complex sensing biomechanical stress via titin's N2B domain to activate MAPK-mediated hypertrophic signaling; (2) promotes skeletal muscle hypertrophy and myoblast differentiation by binding and activating the calcineurin/NFATc1 transcription factor axis; (3) undergoes Src-mediated phosphorylation at Y149/Y272 that switches its function from tumor suppressor (cytoplasmic, interacting with focal adhesion proteins including Kindlin-2 and Talin1) to oncogenic nuclear factor (binding BCLAF1); (4) interacts directly via its LIM1 domain with the hypervariable domain of chikungunya virus nsP3 to facilitate viral replication complex formation; and (5) produces isoforms (FHL1B/SLIMMER) that localize to the nuclear envelope and interact with RBP-J, Siva-1, lamin A/C, and emerin, with pathogenic missense mutations in the LIM2 or LIM4 domains causing protein aggregation, dominant-negative sequestration of NFATc1, and diverse X-linked myopathies."},"narrative":{"mechanistic_narrative":"FHL1 is a multi-isoform LIM-domain scaffold protein, predominantly expressed in striated muscle, that integrates biomechanical and growth-factor signals to control muscle gene expression, fiber differentiation, and stress hypertrophy [PMID:19033658, PMID:23975679]. In the cardiomyocyte sarcomere it forms a stretch-sensing complex with the titin N2B domain and MAPK components, acting downstream of Gq to drive pathological left-ventricular hypertrophy in a ventricle-specific manner [PMID:19033658, PMID:31980934]; it also assembles into a cytoskeletal complex with PDLIM1, gelsolin, and ACTN1 [PMID:21246116]. A central effector function is its binding to and activation of the calcineurin/NFATc1 axis, which promotes skeletal-muscle hypertrophy, oxidative fiber-type switching, and—via an NFATc1–utrophin axis—can reassemble a substitute glycoprotein complex that ameliorates dystrophic pathology [PMID:19075112, PMID:24087791]. FHL1 expression is itself a signaling node, induced by Wnt/TCF-LEF and HOXD13 and downstream of Rho/CRIK, while its isoforms localize differentially to focal adhesions, actin filaments, the nucleus, and the nuclear envelope, where FHL1B associates with lamin A/C and emerin and FHL1B/SLIMMER binds the proapoptotic protein Siva-1 and RBP-J to repress Notch/EBNA2-dependent transcription [PMID:10480922, PMID:18760388, PMID:19643733, PMID:27911330, PMID:25676585, PMID:18758158, PMID:16061799]. In cancer, FHL1 functions as a Src-regulated tumor suppressor: Src-Cas signaling silences FHL1 via promoter methylation, and Src phosphorylation at Y149/Y272 drives nuclear translocation and BCLAF1 binding, with Kindlin-2 and the deubiquitinase OTUD1 opposing this switch [PMID:16452211, PMID:29434030, PMID:36929488]. FHL1 is also an essential host factor for chikungunya and O'nyong-nyong virus replication, binding the nsP3 hypervariable domain through its LIM1 domain [PMID:31554973, PMID:33055253, PMID:37884534]. Pathogenic missense mutations in the LIM2/LIM4 domains cause dominant-negative protein aggregation that sequesters wild-type FHL1 and NFATc1, producing reducing body myopathy and related X-linked myopathies [PMID:18274675, PMID:24634512, PMID:20633900].","teleology":[{"year":1999,"claim":"Established that FHL1 isoforms occupy distinct subcellular compartments, framing it as a protein whose function is partitioned between focal-adhesion signaling and nuclear-cytoplasmic communication.","evidence":"GFP-fusion live imaging and NLS/NES truncation analysis in COS-7 and myoblast/myotube cells","pmids":["10480922"],"confidence":"High","gaps":["Functional consequences of each localization not defined","Did not identify binding partners at focal adhesions or nucleus"]},{"year":2001,"claim":"Showed isoform-specific nuclear targeting and tissue distribution (FHL1B brain-specific; FHL1C distributed via an RBP-J binding region), connecting FHL1 isoforms to transcriptional machinery.","evidence":"Isoform-specific immunoblot, subcellular fractionation, and tagged-isoform transfection","pmids":["11400158"],"confidence":"Medium","gaps":["Single lab, antibody-based","Functional role of RBP-J interaction not yet tested"]},{"year":2003,"claim":"Linked FHL1 overexpression to integrin-dependent myocyte morphology, indicating a role in cell-shape and adhesion signaling during differentiation.","evidence":"Overexpression with alpha5beta1-integrin peptide blockade and substrate controls in myocytes","pmids":["12917103"],"confidence":"Medium","gaps":["Mechanism of integrin engagement unresolved","Overexpression-based; endogenous role untested"]},{"year":2005,"claim":"Placed FHL1 (KyoT1/2) downstream of Rho/CRIK signaling as a suppressor of keratinocyte differentiation, extending its regulatory role beyond muscle.","evidence":"RhoA/CRIK manipulation and KyoT1/2 overexpression with differentiation assays in keratinocytes","pmids":["16061799"],"confidence":"Medium","gaps":["Direct FHL1 effector targets in keratinocytes unknown","Single lab epistasis"]},{"year":2006,"claim":"Identified FHL1 as a tumor suppressor whose silencing by promoter methylation is required for Src-driven transformation, defining the Src-Cas-FHL1 axis.","evidence":"Genome-wide expression analysis with Src/Cas manipulation and transformation assays in tumor cells","pmids":["16452211"],"confidence":"Medium","gaps":["Downstream tumor-suppressive effectors of FHL1 not identified here","Correlative methylation link"]},{"year":2008,"claim":"Established FHL1 as a cardiac biomechanical stress sensor acting downstream of Gq, by tying it to titin N2B and MAPK signaling in hypertrophy.","evidence":"Fhl1 knockout mice with TAC, Gq transgenic epistasis, and Co-IP with titin N2B/MAPK components","pmids":["19033658"],"confidence":"High","gaps":["Precise stretch-to-MAPK transduction step undefined","Stoichiometry of the sarcomeric complex unknown"]},{"year":2008,"claim":"Identified FHL1 as the gene mutated in reducing body myopathy and showed mutants form dominant-negative aggregates, defining a gain-of-toxicity disease mechanism.","evidence":"Laser microdissection proteomics of inclusions plus mutant FHL1 transfection in COS-7/C2C12 cells","pmids":["18274675"],"confidence":"High","gaps":["Why specific LIM mutations aggregate not yet defined","Spectrum of trapped proteins incomplete"]},{"year":2008,"claim":"Refined the tumor-suppressor mechanism by showing Src promotes FHL1 promoter methylation independently of MAPK and that FHL1 induces Sdpr in tumors.","evidence":"Bisulfite sequencing, MAPK inhibitor epistasis, and tumor expression arrays/IHC","pmids":["18422756"],"confidence":"Medium","gaps":["Direct enzymatic link from Src/Cas to DNA methylation not shown","Sdpr functional contribution untested"]},{"year":2008,"claim":"Identified Talin1 as an FHL1 partner in pulmonary artery smooth muscle and tied FHL1 to migration/proliferation in pulmonary hypertension.","evidence":"Proteomics, siRNA/overexpression, and Co-IP with Talin1 in primary human PASMCs","pmids":["18725486"],"confidence":"Medium","gaps":["Functional requirement of the Talin1 interaction not dissected","Single disease context"]},{"year":2008,"claim":"Showed KyoT3/FHL1 represses RBP-J-dependent transactivation, linking an FHL1 isoform to Notch/EBNA2 transcriptional control.","evidence":"EGFP localization, Co-IP with RBP-J, and luciferase reporter assays","pmids":["18760388"],"confidence":"Medium","gaps":["Physiological context of Notch repression unclear","Reporter-based functional readout"]},{"year":2008,"claim":"Demonstrated that HOXD13 directly binds the FHL1 promoter in developing limb, placing FHL1 in a developmental transcriptional program.","evidence":"Luciferase, EMSA, and ChIP from developing rat limb","pmids":["18758158"],"confidence":"Medium","gaps":["Functional consequence of FHL1 in limb development not tested","Single developmental system"]},{"year":2009,"claim":"Showed SLIMMER/FHL1B binds the proapoptotic Siva-1 and delays apoptosis, assigning an isoform-specific survival function with dynamic localization across differentiation.","evidence":"Yeast two-hybrid, direct binding, GST pulldown from muscle, co-localization, and apoptosis assay in C2C12","pmids":["19643733"],"confidence":"High","gaps":["Mechanism by which FHL1B blocks Siva-1 apoptosis undefined","In vivo relevance untested"]},{"year":2009,"claim":"Identified RIP140 as an FHL1 partner enhancing repression of estrogen-responsive transcription, extending FHL1 into nuclear-receptor corepression.","evidence":"Yeast two-hybrid, Co-IP, reporter assays, and siRNA in mammalian cells","pmids":["19401155"],"confidence":"Medium","gaps":["Whether all FHL1 LIM domains directly contact RIP140 not structurally resolved","Single lab"]},{"year":2010,"claim":"Established the FHL1-NFATc1 axis as the core effector for skeletal muscle hypertrophy and showed disease mutants sequester NFATc1, unifying hypertrophic and myopathic mechanisms.","evidence":"Reciprocal Co-IP, calcineurin-inhibitor rescue in C2C12, NFATc1 localization, and FHL1 transgenic mice","pmids":["19075112"],"confidence":"High","gaps":["Direct biochemical step by which FHL1 potentiates NFATc1 unclear","Other calcineurin pathway nodes untested"]},{"year":2011,"claim":"Defined FHL1 binding to the ER AF-1 domain and repression of estrogen-responsive promoters, broadening its corepressor role to estrogen receptor signaling.","evidence":"Co-IP, ChIP, reporter assays, and siRNA knockdown in breast cancer cells","pmids":["19840196"],"confidence":"Medium","gaps":["Relationship to FHL1-RIP140 corepression not integrated","Single lab"]},{"year":2011,"claim":"Defined a native FHL1 cytoskeletal complex (PDLIM1, gelsolin, ACTN1) in heart, supporting its scaffold function at the sarcomere.","evidence":"Tandem affinity purification-MS in HEK-293, reciprocal Co-IP in mouse heart, and 3D microscopy","pmids":["21246116"],"confidence":"Medium","gaps":["Functional role of each complex member with FHL1 not dissected","Stoichiometry unknown"]},{"year":2013,"claim":"Demonstrated FHL1A is required in vivo for muscle fiber differentiation/maturation and that loss causes age-dependent myopathy with autophagy upregulation.","evidence":"FHL1-null mice with histology/EM/function and isoform-specific FHL1A rescue in primary myoblasts","pmids":["23975679"],"confidence":"High","gaps":["Mechanism linking FHL1 loss to autophagy increase undefined here","Isoform-specific contributions only partially separated"]},{"year":2013,"claim":"Extended the FHL1-NFATc1 axis to drive utrophin expression and rescue dystrophic muscle, establishing a therapeutically relevant FHL1-NFATc1-utrophin pathway.","evidence":"FHL1 transgenic/mdx double-mutant mice, utrophin promoter reporter, and membrane stability/function assays","pmids":["24087791"],"confidence":"High","gaps":["Durability and translatability of utrophin induction not addressed","Direct NFATc1-utrophin promoter occupancy not fully mapped"]},{"year":2014,"claim":"Showed disease mutants segregate by phenotype—aggregation (RBM/SPM/XMPMA) versus reduced expression (HCM/EDMD)—and confirmed FHL1 acts through NFATc1 in differentiation via rescue.","evidence":"Disease-mutant expression in C2C12, Menadione-NBT staining, and constitutively active NFATc1 rescue","pmids":["24634512"],"confidence":"Medium","gaps":["Why mutation class dictates aggregation vs degradation unclear","Cell-line based"]},{"year":2014,"claim":"Revealed that cardiac stress reprograms Fhl1 transcriptional start-site usage to produce a protective stress isoform, redefining FHL1 as an adaptive HCM response.","evidence":"5'RNA-Seq, Fhl1 ablation in HCM mice, isoform detection, and human cardiomyopathy samples","pmids":["24509080"],"confidence":"Medium","gaps":["Function of the stress-specific isoform not biochemically defined","Reconciliation with FHL1's pro-hypertrophic role needed"]},{"year":2015,"claim":"Showed FHL1 potentiates myostatin/TGFβ-SMAD signaling to promote muscle atrophy, revealing a context-dependent atrophic function opposing its hypertrophic role.","evidence":"SMAD reporter, myotube wasting, and in vivo FHL1/myostatin co-electroporation","pmids":["26504741"],"confidence":"Medium","gaps":["Molecular step by which FHL1 amplifies SMAD signaling unknown","Reconciliation with pro-hypertrophic NFATc1 role unresolved"]},{"year":2015,"claim":"Identified FHL1 as a granzyme B substrate and autoantigen in inflammatory myopathy, linking FHL1 fragmentation to muscle autoimmunity.","evidence":"Granzyme B cleavage assay, anti-FHL1 autoantibody ELISA in patients, and myositis-prone mouse immunization","pmids":["26551678"],"confidence":"Medium","gaps":["Causal chain from cleavage to autoantibody generation incomplete","Single lab patient cohort"]},{"year":2015,"claim":"Established FHL1 as a Wnt/TCF-LEF transcriptional target required for myotube formation, identifying an upstream regulator of FHL1 in myogenesis.","evidence":"Fhl1 promoter reporter, TCF/LEF site mutagenesis, β-catenin/LiCl treatment, and siRNA in C2C12","pmids":["25676585"],"confidence":"Medium","gaps":["In vivo Wnt-FHL1 dependence not tested","Other myogenic inputs not compared"]},{"year":2016,"claim":"Localized FHL1B to the nuclear envelope with lamin A/C and emerin and showed its dysregulation in EDMD patient myoblasts, connecting an FHL1 isoform to nuclear-envelope myopathy.","evidence":"Immunofluorescence, western blot, and fractionation in primary human and EDMD-patient myoblasts","pmids":["27911330"],"confidence":"Medium","gaps":["Functional role of FHL1B at the nuclear envelope unresolved","Whether FHL1B elevation is compensatory or pathogenic unclear"]},{"year":2018,"claim":"Defined the phosphorylation switch converting FHL1 from cytoplasmic tumor suppressor to nuclear oncogenic factor, with Kindlin-2 antagonizing Src at focal adhesions.","evidence":"Src kinase assay, Y149/Y272 mutagenesis, Co-IP with BCLAF1 and Kindlin-2, fractionation, and proliferation assays","pmids":["29434030"],"confidence":"High","gaps":["BCLAF1 target genes driving growth not identified","Tissue contexts where switch operates limited"]},{"year":2019,"claim":"Linked FHL1 to LC3 and autophagosome formation in myoblast differentiation and anti-atrophy regulation, integrating FHL1 into autophagy control.","evidence":"FHL1-LC3 Co-IP/co-IF and siRNA/overexpression with autophagy/atrophy marker readouts in chicken myoblasts","pmids":["31637727"],"confidence":"Medium","gaps":["Whether FHL1-LC3 binding is direct unproven","Cross-species generalization to mammalian muscle untested"]},{"year":2019,"claim":"Identified FHL1 as an essential host factor for CHIKV replication through direct binding of the nsP3 hypervariable domain, establishing a proviral function.","evidence":"FHL1 KO/knockdown cells, direct binding, replication assays, re-expression rescue, and Fhl1-KO mice","pmids":["31554973"],"confidence":"High","gaps":["Mechanistic role of FHL1 in replication complex assembly undefined here","Which LIM domain mediates binding not yet resolved"]},{"year":2020,"claim":"Mapped the FHL1-nsP3 interaction to the LIM1 domain at a site overlapping CD2AP, providing structural resolution of the proviral interface.","evidence":"NMR structural mapping, LIM truncation analysis, and CHIKV replication/competition assays","pmids":["33055253"],"confidence":"High","gaps":["Whether host LIM1 function is hijacked or merely scaffolds nsP3 unclear","Single lab"]},{"year":2020,"claim":"Showed FHL1-mediated hypertrophic signaling is ventricle-specific, required for LV but dispensable for RV pressure-overload hypertrophy.","evidence":"FHL1-/- mice with pulmonary arterial banding versus aortic constriction and echocardiography","pmids":["31980934"],"confidence":"Medium","gaps":["Basis for ventricle-specific dependence unknown","Compensating factors in RV not identified"]},{"year":2022,"claim":"Revealed a post-translational FHL1 mechanism promoting blastocyst-epithelial adhesion via HOXA10 stabilization through SIRT2-mediated deacetylation and downstream integrin/FAK activation.","evidence":"FHL1 overexpression/knockdown, mouse uterine knockdown, HOXA10-SIRT2 Co-IP, stability assays, and SIRT2 inhibitors","pmids":["36418297"],"confidence":"Medium","gaps":["How FHL1 enhances HOXA10-SIRT2 binding not biochemically defined","Single reproductive context"]},{"year":2023,"claim":"Demonstrated virus-specific requirement for FHL1 in vivo (CHIKV/ONNV but not RRV/MAYV) and that a non-binding viral mutant is avirulent, validating FHL1 as a therapeutic and vaccine target.","evidence":"FHL1-/- mice infected with multiple alphaviruses, nsP3 pull-downs, and engineered CHIKV-ΔFHL1 challenge studies","pmids":["37884534"],"confidence":"High","gaps":["Why some alphavirus nsP3 fail to bind FHL1 unresolved","Host signaling consequences of FHL1 hijacking unknown"]},{"year":2023,"claim":"Identified OTUD1 as a deubiquitinase that stabilizes FHL1 to restrain lung adenocarcinoma, adding post-translational control to FHL1's tumor-suppressor regulation.","evidence":"IP-MS, Co-IP, protein-level assays with OTUD1 manipulation, and in vitro/in vivo tumor growth","pmids":["36929488"],"confidence":"Medium","gaps":["The opposing E3 ligase ubiquitinating FHL1 not identified","Integration with Src-driven FHL1 silencing unresolved"]},{"year":null,"claim":"How a single LIM-domain scaffold reconciles opposing roles—pro-hypertrophic NFATc1 activation versus pro-atrophic myostatin amplification, tumor suppression versus phospho-driven oncogenesis—through isoform identity, post-translational modification, and partner selection remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking isoform/PTM state to functional output","Structural basis of LIM-domain partner discrimination undefined","Direct enzymatic activity, if any, of FHL1 unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[2,3,14]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,8,12,13,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,11,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,11,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,7,8,11,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,11]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[2,3,14]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[23]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3,20]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,11,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[15,19,26,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,5,27,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,12,13,19]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[0,15,32]}],"complexes":["FHL1-titin N2B sarcomeric stretch-sensor complex","FHL1-PDLIM1-gelsolin-ACTN1 cytoskeletal complex"],"partners":["TTN","NFATC1","BCLAF1","FERMT2","TLN1","RBPJ","SIVA1","PDLIM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13642","full_name":"Four and a half LIM domains protein 1","aliases":["Skeletal muscle LIM-protein 1","SLIM","SLIM-1"],"length_aa":323,"mass_kda":36.3,"function":"May have an involvement in muscle development or hypertrophy","subcellular_location":"Nucleus; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/Q13642/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FHL1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"AKAP12","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/FHL1","total_profiled":1310},"omim":[{"mim_id":"619802","title":"IMMUNODEFICIENCY 97 WITH AUTOINFLAMMATION; IMD97","url":"https://www.omim.org/entry/619802"},{"mim_id":"618998","title":"IMMUNE DYSREGULATION AND SYSTEMIC HYPERINFLAMMATION SYNDROME; IMDYSHI","url":"https://www.omim.org/entry/618998"},{"mim_id":"609814","title":"COMPLEMENT FACTOR H DEFICIENCY; CFHD","url":"https://www.omim.org/entry/609814"},{"mim_id":"609424","title":"RING FINGER AND CCCH-TYPE ZINC FINGER DOMAINS-CONTAINING 1; RC3H1","url":"https://www.omim.org/entry/609424"},{"mim_id":"602790","title":"FOUR-AND-A-HALF LIM DOMAINS 3; FHL3","url":"https://www.omim.org/entry/602790"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Cytosol","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":10741.5},{"tissue":"tongue","ntpm":9124.0}],"url":"https://www.proteinatlas.org/search/FHL1"},"hgnc":{"alias_symbol":["SLIM1","KYO-T","bA535K18.1","FHL1B","XMPMA","FLH1A","MGC111107"],"prev_symbol":[]},"alphafold":{"accession":"Q13642","domains":[{"cath_id":"-","chopping":"67-97","consensus_level":"medium","plddt":90.7526,"start":67,"end":97},{"cath_id":"2.10.110.10","chopping":"102-157","consensus_level":"high","plddt":91.6716,"start":102,"end":157},{"cath_id":"2.10.110.10","chopping":"174-236","consensus_level":"high","plddt":81.974,"start":174,"end":236}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13642","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13642-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13642-F1-predicted_aligned_error_v6.png","plddt_mean":72.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FHL1","jax_strain_url":"https://www.jax.org/strain/search?query=FHL1"},"sequence":{"accession":"Q13642","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13642.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13642/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13642"}},"corpus_meta":[{"pmid":"19033658","id":"PMC_19033658","title":"An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice.","date":"2008","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19033658","citation_count":203,"is_preprint":false},{"pmid":"14607842","id":"PMC_14607842","title":"Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14607842","citation_count":183,"is_preprint":false},{"pmid":"11120693","id":"PMC_11120693","title":"Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays.","date":"2000","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11120693","citation_count":179,"is_preprint":false},{"pmid":"19716112","id":"PMC_19716112","title":"Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19716112","citation_count":177,"is_preprint":false},{"pmid":"17399790","id":"PMC_17399790","title":"Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17399790","citation_count":155,"is_preprint":false},{"pmid":"18274675","id":"PMC_18274675","title":"Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy.","date":"2008","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18274675","citation_count":131,"is_preprint":false},{"pmid":"16925556","id":"PMC_16925556","title":"Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1.","date":"2006","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16925556","citation_count":128,"is_preprint":false},{"pmid":"18179888","id":"PMC_18179888","title":"An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1.","date":"2008","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18179888","citation_count":126,"is_preprint":false},{"pmid":"22291192","id":"PMC_22291192","title":"Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1, FHR-1, and C4BP.","date":"2012","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22291192","citation_count":120,"is_preprint":false},{"pmid":"19075112","id":"PMC_19075112","title":"Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19075112","citation_count":113,"is_preprint":false},{"pmid":"12183569","id":"PMC_12183569","title":"The yeast Candida albicans binds complement regulators factor H and FHL-1.","date":"2002","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12183569","citation_count":108,"is_preprint":false},{"pmid":"17959597","id":"PMC_17959597","title":"Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17959597","citation_count":106,"is_preprint":false},{"pmid":"22523091","id":"PMC_22523091","title":"Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22523091","citation_count":101,"is_preprint":false},{"pmid":"10480922","id":"PMC_10480922","title":"Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10480922","citation_count":91,"is_preprint":false},{"pmid":"19850343","id":"PMC_19850343","title":"Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, FHL-1 and plasminogen binding surface protein.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19850343","citation_count":91,"is_preprint":false},{"pmid":"9714789","id":"PMC_9714789","title":"Chromosomal mapping, tissue distribution and cDNA sequence of four-and-a-half LIM domain protein 1 (FHL1).","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9714789","citation_count":85,"is_preprint":false},{"pmid":"8164651","id":"PMC_8164651","title":"Suppression of yeast RNA polymerase III mutations by FHL1, a gene coding for a fork head protein involved in rRNA processing.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8164651","citation_count":84,"is_preprint":false},{"pmid":"12402151","id":"PMC_12402151","title":"Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12402151","citation_count":79,"is_preprint":false},{"pmid":"19181672","id":"PMC_19181672","title":"Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.","date":"2009","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19181672","citation_count":78,"is_preprint":false},{"pmid":"31554973","id":"PMC_31554973","title":"FHL1 is a major host factor for chikungunya virus infection.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31554973","citation_count":74,"is_preprint":false},{"pmid":"10049693","id":"PMC_10049693","title":"The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10049693","citation_count":74,"is_preprint":false},{"pmid":"18725486","id":"PMC_18725486","title":"Fhl-1, a new key protein in pulmonary hypertension.","date":"2008","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/18725486","citation_count":72,"is_preprint":false},{"pmid":"18422756","id":"PMC_18422756","title":"Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18422756","citation_count":71,"is_preprint":false},{"pmid":"21702045","id":"PMC_21702045","title":"Downregulation and growth inhibitory role of FHL1 in lung cancer.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21702045","citation_count":65,"is_preprint":false},{"pmid":"19687455","id":"PMC_19687455","title":"Consequences of mutations within the C terminus of the FHL1 gene.","date":"2009","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19687455","citation_count":61,"is_preprint":false},{"pmid":"24509080","id":"PMC_24509080","title":"5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24509080","citation_count":55,"is_preprint":false},{"pmid":"18952429","id":"PMC_18952429","title":"Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1).","date":"2008","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/18952429","citation_count":53,"is_preprint":false},{"pmid":"16452211","id":"PMC_16452211","title":"SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16452211","citation_count":52,"is_preprint":false},{"pmid":"12917103","id":"PMC_12917103","title":"Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces alpha 5 beta 1-integrin-dependent myocyte elongation.","date":"2003","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12917103","citation_count":50,"is_preprint":false},{"pmid":"20186852","id":"PMC_20186852","title":"Contractures and hypertrophic cardiomyopathy in a novel FHL1 mutation.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20186852","citation_count":50,"is_preprint":false},{"pmid":"25272045","id":"PMC_25272045","title":"MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25272045","citation_count":50,"is_preprint":false},{"pmid":"22094483","id":"PMC_22094483","title":"Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy.","date":"2011","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22094483","citation_count":48,"is_preprint":false},{"pmid":"19840196","id":"PMC_19840196","title":"FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19840196","citation_count":46,"is_preprint":false},{"pmid":"11400158","id":"PMC_11400158","title":"Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1).","date":"2001","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11400158","citation_count":45,"is_preprint":false},{"pmid":"23975679","id":"PMC_23975679","title":"Loss of FHL1 induces an age-dependent skeletal muscle myopathy associated with myofibrillar and intermyofibrillar disorganization in mice.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23975679","citation_count":43,"is_preprint":false},{"pmid":"22689052","id":"PMC_22689052","title":"FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22689052","citation_count":42,"is_preprint":false},{"pmid":"31824478","id":"PMC_31824478","title":"Enolase From Aspergillus fumigatus Is a Moonlighting Protein That Binds the Human Plasma Complement Proteins Factor H, FHL-1, C4BP, and Plasminogen.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31824478","citation_count":41,"is_preprint":false},{"pmid":"20633900","id":"PMC_20633900","title":"A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations.","date":"2010","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20633900","citation_count":39,"is_preprint":false},{"pmid":"10860860","id":"PMC_10860860","title":"The LIM-domain protein FHL1 (SLIM 1) exhibits functional regulation in skeletal muscle.","date":"2000","source":"Molecular cell biology research communications : MCBRC","url":"https://pubmed.ncbi.nlm.nih.gov/10860860","citation_count":38,"is_preprint":false},{"pmid":"26551678","id":"PMC_26551678","title":"Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26551678","citation_count":37,"is_preprint":false},{"pmid":"10352231","id":"PMC_10352231","title":"Genomic structure, tissue expression and chromosomal location of the LIM-only gene, SLIM1.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10352231","citation_count":36,"is_preprint":false},{"pmid":"10524257","id":"PMC_10524257","title":"Characterization of a brain-specific nuclear LIM domain protein (FHL1B) which is an alternatively spliced variant of FHL1.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10524257","citation_count":36,"is_preprint":false},{"pmid":"23965743","id":"PMC_23965743","title":"Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders.","date":"2013","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23965743","citation_count":36,"is_preprint":false},{"pmid":"18465173","id":"PMC_18465173","title":"Clinical significance of loss of Fhl1 expression in human gastric cancer.","date":"2008","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18465173","citation_count":34,"is_preprint":false},{"pmid":"19401155","id":"PMC_19401155","title":"Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19401155","citation_count":33,"is_preprint":false},{"pmid":"20571991","id":"PMC_20571991","title":"Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1.","date":"2010","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20571991","citation_count":33,"is_preprint":false},{"pmid":"12780697","id":"PMC_12780697","title":"Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis.","date":"2003","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12780697","citation_count":33,"is_preprint":false},{"pmid":"30745459","id":"PMC_30745459","title":"Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30745459","citation_count":32,"is_preprint":false},{"pmid":"17160605","id":"PMC_17160605","title":"Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi.","date":"2006","source":"Wiener klinische Wochenschrift","url":"https://pubmed.ncbi.nlm.nih.gov/17160605","citation_count":32,"is_preprint":false},{"pmid":"22143536","id":"PMC_22143536","title":"Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22143536","citation_count":31,"is_preprint":false},{"pmid":"17174532","id":"PMC_17174532","title":"Altered expression of FHL1, CARP, TSC-22 and P311 provide insights into complex transcriptional regulation in pacing-induced atrial fibrillation.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17174532","citation_count":31,"is_preprint":false},{"pmid":"21246116","id":"PMC_21246116","title":"Identification of an FHL1 protein complex containing ACTN1, ACTN4, and PDLIM1 using affinity purifications and MS-based protein-protein interaction analysis.","date":"2011","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/21246116","citation_count":27,"is_preprint":false},{"pmid":"16061799","id":"PMC_16061799","title":"Negative control of keratinocyte differentiation by Rho/CRIK signaling coupled with up-regulation of KyoT1/2 (FHL1) expression.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16061799","citation_count":27,"is_preprint":false},{"pmid":"31632001","id":"PMC_31632001","title":"Overexpression Of hsa-miR-664a-3p Is Associated With Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Via Targeting FHL1.","date":"2019","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/31632001","citation_count":27,"is_preprint":false},{"pmid":"22172421","id":"PMC_22172421","title":"Reducing body myopathy and other FHL1-related muscular disorders.","date":"2011","source":"Seminars in pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22172421","citation_count":26,"is_preprint":false},{"pmid":"29434030","id":"PMC_29434030","title":"Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter.","date":"2018","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29434030","citation_count":26,"is_preprint":false},{"pmid":"26504741","id":"PMC_26504741","title":"FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy.","date":"2015","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/26504741","citation_count":26,"is_preprint":false},{"pmid":"23489660","id":"PMC_23489660","title":"Proteomic characterization of aggregate components in an intrafamilial variable FHL1-associated myopathy.","date":"2013","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/23489660","citation_count":26,"is_preprint":false},{"pmid":"23169582","id":"PMC_23169582","title":"Novel FHL1 mutation in a family with reducing body myopathy.","date":"2012","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/23169582","citation_count":25,"is_preprint":false},{"pmid":"10329211","id":"PMC_10329211","title":"The cardiac expression of striated muscle LIM protein 1 (SLIM1) is restricted to the outflow tract of the developing heart.","date":"1999","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/10329211","citation_count":24,"is_preprint":false},{"pmid":"31637727","id":"PMC_31637727","title":"FHL1 regulates myoblast differentiation and autophagy through its interaction with LC3.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31637727","citation_count":24,"is_preprint":false},{"pmid":"24702793","id":"PMC_24702793","title":"Structural characterization of CspZ, a complement regulator factor H and FHL-1 binding protein from Borrelia burgdorferi.","date":"2014","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/24702793","citation_count":24,"is_preprint":false},{"pmid":"24634512","id":"PMC_24634512","title":"FHL1 mutants that cause clinically distinct human myopathies form protein aggregates and impair myoblast differentiation.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24634512","citation_count":23,"is_preprint":false},{"pmid":"19138559","id":"PMC_19138559","title":"Mutational analyses of the BbCRASP-1 protein of Borrelia burgdorferi identify residues relevant for the architecture and binding of host complement regulators FHL-1 and factor H.","date":"2009","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/19138559","citation_count":23,"is_preprint":false},{"pmid":"27443559","id":"PMC_27443559","title":"Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy.","date":"2016","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/27443559","citation_count":23,"is_preprint":false},{"pmid":"18760388","id":"PMC_18760388","title":"KyoT3, an isoform of murine FHL1, associates with the transcription factor RBP-J and represses the RBP-J-mediated transactivation.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18760388","citation_count":23,"is_preprint":false},{"pmid":"31772674","id":"PMC_31772674","title":"Long Intergenic Noncoding RNA 00261 Acts as a Tumor Suppressor in Non-Small Cell Lung Cancer via Regulating miR-105/FHL1 Axis.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31772674","citation_count":22,"is_preprint":false},{"pmid":"29113254","id":"PMC_29113254","title":"Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29113254","citation_count":21,"is_preprint":false},{"pmid":"25676585","id":"PMC_25676585","title":"Estrogen enhances activity of Wnt signaling during osteogenesis by inducing Fhl1 expression.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25676585","citation_count":21,"is_preprint":false},{"pmid":"18758158","id":"PMC_18758158","title":"HOXD13 may play a role in idiopathic congenital clubfoot by regulating the expression of FHL1.","date":"2008","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/18758158","citation_count":21,"is_preprint":false},{"pmid":"16530476","id":"PMC_16530476","title":"Structure-function mapping of BbCRASP-1, the key complement factor H and FHL-1 binding protein of Borrelia burgdorferi.","date":"2006","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/16530476","citation_count":20,"is_preprint":false},{"pmid":"34335951","id":"PMC_34335951","title":"FHL1 Inhibits the Progression of Colorectal Cancer by Regulating the Wnt/β-Catenin Signaling Pathway.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34335951","citation_count":19,"is_preprint":false},{"pmid":"36929488","id":"PMC_36929488","title":"VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinoma.","date":"2023","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36929488","citation_count":19,"is_preprint":false},{"pmid":"23625919","id":"PMC_23625919","title":"The evolutionary rewiring of the ribosomal protein transcription pathway modifies the interaction of transcription factor heteromer Ifh1-Fhl1 (interacts with forkhead 1-forkhead-like 1) with the DNA-binding specificity element.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23625919","citation_count":19,"is_preprint":false},{"pmid":"23500067","id":"PMC_23500067","title":"Left ventricular hypertrophy caused by a novel nonsense mutation in FHL1.","date":"2013","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23500067","citation_count":19,"is_preprint":false},{"pmid":"31273321","id":"PMC_31273321","title":"FHL1-related clinical, muscle MRI and genetic features in six Chinese patients with reducing body myopathy.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31273321","citation_count":19,"is_preprint":false},{"pmid":"33055253","id":"PMC_33055253","title":"Structural and Functional Characterization of Host FHL1 Protein Interaction with Hypervariable Domain of Chikungunya Virus nsP3 Protein.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33055253","citation_count":18,"is_preprint":false},{"pmid":"23456229","id":"PMC_23456229","title":"Dysregulation of FHL1 spliceforms due to an indel mutation produces an Emery-Dreifuss muscular dystrophy plus phenotype.","date":"2013","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23456229","citation_count":18,"is_preprint":false},{"pmid":"31980934","id":"PMC_31980934","title":"FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction.","date":"2020","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/31980934","citation_count":18,"is_preprint":false},{"pmid":"18706858","id":"PMC_18706858","title":"Identification and characterization of the factor H and FHL-1 binding complement regulator-acquiring surface protein 1 of the Lyme disease spirochete Borrelia spielmanii sp. nov.","date":"2008","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/18706858","citation_count":18,"is_preprint":false},{"pmid":"19643733","id":"PMC_19643733","title":"SLIMMER (FHL1B/KyoT3) interacts with the proapoptotic protein Siva-1 (CD27BP) and delays skeletal myoblast apoptosis.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19643733","citation_count":17,"is_preprint":false},{"pmid":"33178228","id":"PMC_33178228","title":"Tuning the Functionality by Splicing: Factor H and Its Alternative Splice Variant FHL-1 Share a Gene but Not All Functions.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33178228","citation_count":17,"is_preprint":false},{"pmid":"25191266","id":"PMC_25191266","title":"Aggresome-Autophagy Involvement in a Sarcopenic Patient with Rigid Spine Syndrome and a p.C150R Mutation in FHL1 Gene.","date":"2014","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25191266","citation_count":17,"is_preprint":false},{"pmid":"23600722","id":"PMC_23600722","title":"AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1.","date":"2013","source":"Fundamental & clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23600722","citation_count":17,"is_preprint":false},{"pmid":"37884534","id":"PMC_37884534","title":"FHL1 promotes chikungunya and o'nyong-nyong virus infection and pathogenesis with implications for alphavirus vaccine design.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37884534","citation_count":16,"is_preprint":false},{"pmid":"26017856","id":"PMC_26017856","title":"FHL1 inhibits the growth of tongue squamous cell carcinoma cells via G1/S cell cycle arrest.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26017856","citation_count":16,"is_preprint":false},{"pmid":"34239032","id":"PMC_34239032","title":"FHL-1 interacts with human RPE cells through the α5β1 integrin and confers protection against oxidative stress.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34239032","citation_count":16,"is_preprint":false},{"pmid":"30083183","id":"PMC_30083183","title":"Aberrant Protein Turn-Over Associated With Myofibrillar Disorganization in FHL1 Knockout Mice.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30083183","citation_count":15,"is_preprint":false},{"pmid":"29735270","id":"PMC_29735270","title":"A zebrafish model for FHL1-opathy reveals loss-of-function effects of human FHL1 mutations.","date":"2018","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/29735270","citation_count":15,"is_preprint":false},{"pmid":"33322515","id":"PMC_33322515","title":"MiR-96-5p Induced by Palmitic Acid Suppresses the Myogenic Differentiation of C2C12 Myoblasts by Targeting FHL1.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33322515","citation_count":15,"is_preprint":false},{"pmid":"22367176","id":"PMC_22367176","title":"Fhl1 as a downstream target of Wnt signaling to promote myogenesis of C2C12 cells.","date":"2012","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22367176","citation_count":15,"is_preprint":false},{"pmid":"27911330","id":"PMC_27911330","title":"FHL1B Interacts with Lamin A/C and Emerin at the Nuclear Lamina and is Misregulated in Emery-Dreifuss Muscular Dystrophy.","date":"2016","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27911330","citation_count":14,"is_preprint":false},{"pmid":"30073757","id":"PMC_30073757","title":"IGF2-derived miR-483-3p associated with Hirschsprung's disease by targeting FHL1.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30073757","citation_count":14,"is_preprint":false},{"pmid":"26857240","id":"PMC_26857240","title":"Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26857240","citation_count":14,"is_preprint":false},{"pmid":"36418297","id":"PMC_36418297","title":"FHL1 mediates HOXA10 deacetylation via SIRT2 to enhance blastocyst-epithelial adhesion.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36418297","citation_count":13,"is_preprint":false},{"pmid":"24087791","id":"PMC_24087791","title":"Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24087791","citation_count":13,"is_preprint":false},{"pmid":"26908444","id":"PMC_26908444","title":"X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26908444","citation_count":13,"is_preprint":false},{"pmid":"25975448","id":"PMC_25975448","title":"Inhibition of FHL1 inhibits cigarette smoke extract-induced proliferation in pulmonary arterial smooth muscle cells.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/25975448","citation_count":13,"is_preprint":false},{"pmid":"17589823","id":"PMC_17589823","title":"Variations in the four and a half LIM domains 1 gene (FHL1) are associated with fasting insulin and insulin sensitivity responses to regular exercise.","date":"2007","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/17589823","citation_count":13,"is_preprint":false},{"pmid":"31293105","id":"PMC_31293105","title":"Molecular autopsy and family screening in a young case of sudden cardiac death reveals an unusually severe case of FHL1 related hypertrophic cardiomyopathy.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31293105","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51338,"output_tokens":8980,"usd":0.144357,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19021,"output_tokens":8610,"usd":0.155177,"stage2_stop_reason":"end_turn"},"total_usd":0.299534,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"FHL1 forms a complex within the cardiomyocyte sarcomere that senses biomechanical stress via the N2B stretch sensor domain of titin and initiates changes in titin- and MAPK-mediated responses important for sarcomere extensibility and intracellular signaling. Fhl1-deficient mice show blunted hypertrophic response to pressure overload, and Fhl1 deficiency prevents cardiomyopathy in Gq transgenic mice, placing FHL1 downstream of Gq signaling in pathological hypertrophy.\",\n      \"method\": \"Fhl1 knockout mice + transverse aortic constriction, Gq transgenic mouse epistasis, co-immunoprecipitation with titin N2B domain and MAPK components\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic epistasis (two independent mouse models), co-immunoprecipitation identifying complex members, loss-of-function with defined molecular and cardiac phenotype\",\n      \"pmids\": [\"19033658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FHL1 binds to the calcineurin-regulated transcription factor NFATc1, enhancing NFATc1 transcriptional activity. FHL1 overexpression promotes skeletal muscle hypertrophy and an oxidative fiber-type switch via this calcineurin/NFATc1 signaling axis; RBM-mutant FHL1 sequesters NFATc1 in aggregates, reducing NFAT nuclear translocation and transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation of FHL1 with NFATc1; calcineurin inhibitor rescue of FHL1-induced hypertrophic myotube phenotype in C2C12 cells; NFATc1 localization studies; FHL1 transgenic mice\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, calcineurin inhibitor epistasis rescue, in vivo transgenic model, multiple orthogonal methods in single study replicated across cell and animal models\",\n      \"pmids\": [\"19075112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SLIM1 (FHL1) localizes to focal adhesions and actin filaments in COS-7 cells. The isoform SLIMMER (FHL1B/KyoT3) localizes to the nucleus of myoblasts via a bipartite nuclear localization signal and is exported to the cytoplasm of myotubes via a leucine-rich nuclear export sequence. These distinct localizations suggest separate roles in focal adhesion signaling versus nuclear-cytoplasmic communication.\",\n      \"method\": \"GFP fusion protein live-cell imaging in COS-7 cells and Sol8 myoblasts/myotubes; truncation mutant analysis of NLS and NES sequences; immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct GFP localization with functional domain dissection by multiple truncation mutants; subcellular localization tied to isoform-specific sequences\",\n      \"pmids\": [\"10480922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SLIM1/FHL1 overexpression in differentiating skeletal myocytes induces alpha5beta1-integrin-dependent hyperelongation; in undifferentiated reserve cells it induces integrin-mediated cytoplasmic branching. These effects were blocked by poly-L-lysine plating or peptide blockade of alpha5beta1-integrin ligand binding, establishing a specific dependence on alpha5beta1-integrin signaling.\",\n      \"method\": \"SLIM1 overexpression in Sol8/C2C12 cells; peptide blockade of alpha5beta1-integrin; poly-L-lysine substrate control; cell morphology analysis\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function peptide blockade plus overexpression, single lab, two orthogonal blocking approaches confirming integrin dependence\",\n      \"pmids\": [\"12917103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FHL1 is identified as the protein mutated in reducing body myopathy (RBM). Mutant FHL1 expressed in COS-7 and C2C12 cells forms aggresome-like inclusions that incorporate both mutant and wild-type FHL1 and trap other proteins in a dominant-negative manner.\",\n      \"method\": \"Laser microdissection of inclusions + nanoflow LC-MS/MS proteomics; transfection of mutant FHL1 into COS-7 and C2C12 cells; immunofluorescence imaging of aggregates\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — novel proteomic identification combined with cell transfection demonstrating dominant-negative aggregate formation, multiple cell types tested\",\n      \"pmids\": [\"18274675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FHL1 interacts directly with the hypervariable domain (HVD) of chikungunya virus nsP3 protein, and this interaction is essential for CHIKV RNA replication. Cells lacking FHL1 are resistant to CHIKV infection; FHL1 expression in non-expressing cells promotes CHIKV infection.\",\n      \"method\": \"FHL1 knockout/knockdown cells, direct binding assay, viral RNA replication assay, FHL1 expression rescue in non-expressing cells, Fhl1-knockout mice infected with CHIKV\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding established, loss-of-function in both cell lines and KO mice, rescue by re-expression, multiple viral strains tested across multiple labs\",\n      \"pmids\": [\"31554973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NMR structural studies revealed that FHL1 binds CHIKV nsP3 HVD predominantly via its LIM1 domain, with the binding site overlapping that of CD2AP. FHL1 and CD2AP have additive proviral effects on CHIKV replication efficiency.\",\n      \"method\": \"NMR-based structural mapping of FHL1-HVD interaction; LIM domain truncation analysis; CHIKV replication assays in FHL1 KO cell lines; competition with CD2AP\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural mapping with domain-level resolution combined with functional viral replication assays; single lab but orthogonal structural and biological methods\",\n      \"pmids\": [\"33055253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FHL1C (KyoT2 homolog) localizes to both nucleus and cytoplasm; its C-terminal RBP-J binding region is required for this distribution. FHL1B localizes predominantly to the nucleus via its C-terminal bipartite NLS and is brain-specifically expressed.\",\n      \"method\": \"Immunoblot with isoform-specific antibodies; subcellular fractionation; transfection of tagged isoforms; RT-PCR tissue distribution\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — immunoblot and transfection-based localization; single lab, multiple isoforms characterized with antibody validation\",\n      \"pmids\": [\"11400158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"KyoT3 (FHL1 isoform) localizes preferentially to the nucleus, interacts with RBP-J via co-immunoprecipitation, and represses RBP-J-dependent transactivation activated by both Notch intracellular domain and EBV nuclear antigen 2.\",\n      \"method\": \"EGFP fusion protein localization; co-immunoprecipitation of KyoT3 with RBP-J; luciferase reporter assay for RBP-J-dependent promoter\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional reporter assay, single lab, two orthogonal methods confirming RBP-J interaction and transcriptional repression\",\n      \"pmids\": [\"18760388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Src phosphorylates Cas to suppress FHL1 expression (via promoter methylation), and suppression of FHL1 is required for Src to promote tumor cell anchorage-independent growth and migration, placing FHL1 downstream of the Src-Cas signaling axis as a tumor suppressor.\",\n      \"method\": \"Gene expression analysis of >14,000 genes; Src and Cas expression/inhibition experiments; anchorage-independent growth and migration assays in tumor cells normalized by non-transformed cell contact\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via Src/Cas manipulation with defined functional phenotype (anchorage-independent growth, migration); single lab\",\n      \"pmids\": [\"16452211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Src promotes FHL1 promoter methylation (via Cas) to suppress FHL1 expression independently of MAPK activity. FHL1 in turn induces Sdpr expression in Src-transformed cells. FHL1 and Sdpr are coordinately suppressed in breast, kidney, and prostate tumors.\",\n      \"method\": \"DNA bisulfite modification and sequencing; MAPK inhibitor treatment; gene expression arrays; immunohistochemistry of tumor vs. normal tissue\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — methylation assay plus MAPK inhibitor epistasis plus gene expression in primary tumors; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18422756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Src phosphorylates FHL1 at Y149 and Y272, causing phosphorylated FHL1 to translocate to the nucleus where it binds the transcription factor BCLAF1 and promotes tumor cell growth. Kindlin-2 interacts with FHL1 at focal adhesions and competes with Src for FHL1 binding, suppressing Src-mediated FHL1 phosphorylation.\",\n      \"method\": \"In vitro Src kinase assay; site-directed mutagenesis of Y149 and Y272; co-immunoprecipitation of FHL1 with BCLAF1 and Kindlin-2; subcellular fractionation; tumor cell proliferation assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — site-directed mutagenesis of phosphorylation sites combined with kinase assay, Co-IP of binding partners, subcellular localization shift, and functional proliferation assay; multiple orthogonal methods\",\n      \"pmids\": [\"29434030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FHL1 physically interacts with estrogen receptors (ERs), specifically binding the activation function-1 (AF-1) domain of ER. This interaction is required for FHL1 repression of estrogen-responsive gene transcription; FHL1 affects ER recruitment to estrogen-responsive promoters.\",\n      \"method\": \"Co-immunoprecipitation; chromatin immunoprecipitation (ChIP); luciferase reporter assays; FHL1 siRNA knockdown; overexpression in breast cancer cells\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying AF-1 binding domain, ChIP showing ER promoter recruitment changes, and siRNA rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19840196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FHL1 interacts with RIP140 (receptor interacting protein of 140 kDa) in vitro and in mammalian cells; estrogen enhances this interaction. All domains of FHL1 are required for RIP140 binding. FHL1 enhances RIP140 repression of estrogen signaling and synergistically inhibits transcription of the estrogen-responsive gene pS2.\",\n      \"method\": \"Yeast two-hybrid screening; co-immunoprecipitation in mammalian cells; luciferase reporter assay; FHL1 siRNA knockdown; FHL1 domain deletion mutants\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP in mammalian cells plus functional reporter assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19401155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FHL1 exists as part of a protein complex that includes PDLIM1, gelsolin (GSN), and ACTN1 (alpha-actinin 1), as identified by tandem affinity purification from HEK-293 cells confirmed by immunoprecipitation from mouse heart ventricles and 3D fluorescence microscopy in adult cardiomyocytes.\",\n      \"method\": \"Tandem affinity purification from HEK-293 cells; LC-MS identification of interactors; reciprocal immunoprecipitation from mouse heart ventricles; 3D fluorescence microscopy\",\n      \"journal\": \"Molecular bioSystems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity purification-MS plus reciprocal Co-IP in native cardiac tissue; single lab, two orthogonal methods with biological validation\",\n      \"pmids\": [\"21246116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss of FHL1 in mice leads to an age-dependent skeletal muscle myopathy with myofibrillar and intermyofibrillar disorganization, impaired oxidative capacity, and increased autophagic activity. Re-expression of the FHL1A isoform specifically rescues early muscle fiber differentiation and maturation defects in primary FHL1-null myoblasts, establishing FHL1A as necessary for proper muscle fiber differentiation.\",\n      \"method\": \"FHL1-null mice; histological, ultrastructural (EM), and functional muscle analyses; primary myoblast isolation and re-expression of FHL1A isoform; longitudinal survival study\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete KO mouse model with longitudinal analysis, rescue by isoform-specific re-expression, multiple orthogonal histological/functional readouts\",\n      \"pmids\": [\"23975679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Rho/CRIK signaling suppresses keratinocyte differentiation through up-regulation of KyoT1/2 (FHL1) expression. Elevated KyoT1/2 expression suppresses differentiation similarly to activated Rho and CRIK, placing FHL1 downstream of the Rho-CRIK pathway in keratinocyte self-renewal/differentiation control.\",\n      \"method\": \"RhoA and CRIK overexpression/inhibition in keratinocytes; gene expression analysis; KyoT1/2 overexpression in keratinocytes with differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis placing FHL1 downstream of Rho/CRIK with defined differentiation phenotype; single lab, multiple genetic manipulations\",\n      \"pmids\": [\"16061799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FHL1 activates myostatin signaling; FHL1 increases myostatin activity on a SMAD reporter and increases myostatin-dependent myotube wasting. Co-expression of FHL1 and myostatin in mice reduced fiber diameter to a greater extent than myostatin alone, demonstrating that FHL1 can promote muscle atrophy by potentiating TGFβ/myostatin-SMAD signaling.\",\n      \"method\": \"SMAD luciferase reporter assay; myotube wasting assay; in vivo electroporation of FHL1 and myostatin into mouse muscle; fiber diameter measurement\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus in vivo co-expression epistasis; single lab, two orthogonal methods\",\n      \"pmids\": [\"26504741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SLIMMER (FHL1B/KyoT3) interacts with the proapoptotic protein Siva-1 via yeast two-hybrid, direct binding, and GST pulldown from skeletal muscle lysates. SLIMMER and Siva-1 co-localize in the nucleus of C2C12 myoblasts and redistribute to the cytoplasm upon differentiation, and to the Z-line in mature skeletal muscle. SLIMMER delays Siva-1-dependent apoptosis in C2C12 myoblasts.\",\n      \"method\": \"Yeast two-hybrid screen; direct binding assay; GST pulldown from muscle lysates; co-localization by immunofluorescence; apoptosis assay in C2C12 myoblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three orthogonal protein interaction methods (yeast two-hybrid, direct binding, GST pulldown) plus co-localization and functional apoptosis assay; single lab but rigorous multi-method approach\",\n      \"pmids\": [\"19643733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FHL1 overexpression promotes NFATc1 activation of the utrophin promoter and increases sarcolemmal expression of utrophin in mdx mice, directing assembly of a substitute utrophin-glycoprotein complex, thereby ameliorating dystrophic pathology. This defines a novel FHL1-NFATc1-utrophin signaling axis.\",\n      \"method\": \"FHL1 transgenic/mdx double-mutant mice; utrophin promoter-luciferase reporter assay; sarcolemmal membrane stability assays; immunohistochemistry; muscle function tests\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo double-mutant mouse model, reporter assay defining FHL1-NFATc1-utrophin pathway, multiple functional and molecular readouts; single lab but comprehensive approach\",\n      \"pmids\": [\"24087791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FHL1 expression in pulmonary artery smooth muscle cells is upregulated in pulmonary hypertension. FHL1 knockdown suppresses, while FHL1 overexpression increases, PASMC migration and proliferation. Co-immunoprecipitation identified Talin1 as a new FHL1-interacting partner in this context.\",\n      \"method\": \"2D-PAGE proteomics; siRNA knockdown; adenoviral overexpression; co-immunoprecipitation with Talin1; migration and proliferation assays in primary human PASMCs\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying Talin1 interaction, siRNA/overexpression functional assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18725486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RBM and SPM FHL1 mutations affecting conserved zinc-coordinating residues in the LIM2 domain lead to protein aggregation. Molecular dynamics simulations of LIM2 mutations showed increased nonpolar solvent-accessible surface area without major structural distortion or disruption of zinc binding, suggesting the mutations increase propensity to aggregate.\",\n      \"method\": \"Transfection of mutant FHL1 into C2C12 cells (aggregate formation); molecular dynamics simulations of LIM2 domain mutations; immunohistochemistry of muscle biopsies\",\n      \"journal\": \"Journal of the neurological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — computational structural modeling plus cell transfection aggregate assay; single lab, limited experimental validation of MD predictions\",\n      \"pmids\": [\"20633900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RBM, SPM, and XMPMA FHL1 mutants expressed in C2C12 cells form aggregates positive for the reducing body stain Menadione-NBT and impair myoblast differentiation. HCM and EDMD FHL1 mutants generally show reduced protein expression instead of aggregation. SPM and XMPMA mutant-induced impaired myotube formation is partially rescued by constitutively active NFATc1, confirming FHL1 acts through NFATc1 signaling in myoblast differentiation.\",\n      \"method\": \"Expression of disease mutants in C2C12 cells; Menadione-NBT staining; myotube formation assay; constitutively active NFATc1 rescue experiment; immunofluorescence\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple disease mutants with defined cellular phenotypes; NFATc1 rescue epistasis; single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"24634512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FHL1B isoform localizes to the nuclear envelope of primary human myoblasts, co-localizing with but independently of lamin A/C and emerin. FHL1B protein expression is markedly reduced during myoblast differentiation. FHL1B is elevated in myoblasts from FHL1-related EDMD patients (where the mutation only affects FHL1A) and from LMNA-related EDMD patients.\",\n      \"method\": \"Immunofluorescence of primary human myoblasts; western blotting; subcellular fractionation; analysis of EDMD patient myoblasts\",\n      \"journal\": \"Journal of neuromuscular diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence in primary cells confirmed by western blot; single lab, patient-derived cell validation\",\n      \"pmids\": [\"27911330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FHL1 regulates myoblast differentiation through interaction with LC3; FHL1 and LC3 interact by immunoprecipitation and co-immunofluorescence to regulate autophagosome formation. FHL1 silencing inhibits ATG5 and ATG7 expression, promotes apoptosis (increased cleaved caspase-3 and PARP), and FHL1 rescues skeletal muscle atrophy by regulating Atrogin-1 and MuRF1 expression.\",\n      \"method\": \"FHL1 siRNA knockdown and overexpression in chicken myoblasts; immunoprecipitation of FHL1 with LC3; immunofluorescence co-localization; western blot for autophagy and differentiation markers\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing FHL1-LC3 interaction plus functional knockdown/overexpression with defined molecular and morphological phenotypes; single lab\",\n      \"pmids\": [\"31637727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FHL1 promotes blastocyst-epithelial adhesion by increasing HOXA10 protein stability and activating HOXA10 transcriptional activity via enhanced deacetylation of HOXA10 through increased HOXA10-SIRT2 binding. FHL1 does not regulate HOXA10 mRNA but acts post-translationally; SIRT2-specific inhibitors block this effect. FHL1 also activates the downstream β3 integrin/FAK pathway.\",\n      \"method\": \"FHL1 overexpression/knockdown in endometrial epithelial cells; mouse uterine FHL1 knockdown inhibiting embryo implantation; co-immunoprecipitation of HOXA10-SIRT2; HOXA10 protein stability assays; SIRT2 inhibitor treatment; β3 integrin/FAK pathway analysis\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying HOXA10-SIRT2 interaction mediated by FHL1, in vivo mouse implantation model, pharmacological inhibitor validation; single lab\",\n      \"pmids\": [\"36418297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FHL1 expression is induced by Wnt signaling (β-catenin or LiCl) through TCF/LEF binding sites in the Fhl1 promoter; mutation of two TCF/LEF consensus sites significantly decreases promoter activity. Fhl1 knockdown in C2C12 cells reduces myotube formation, establishing Fhl1 as a downstream effector of Wnt signaling in myogenesis.\",\n      \"method\": \"Fhl1 promoter-luciferase reporter assay; TCF/LEF site mutagenesis; β-catenin and LiCl treatment; Fhl1 siRNA knockdown; myotube formation assay in C2C12 cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis identifying TCF/LEF regulatory elements plus siRNA functional assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25676585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FHL1 is required for CHIKV and ONNV (but not RRV or MAYV) pathogenesis in vivo; FHL1-/- mice infected with CHIKV or ONNV show reduced arthritis, myositis, and immune infiltrates. Pull-down assays confirmed CHIKV and ONNV nsP3 interact with FHL1 while RRV and MAYV nsP3 do not. A CHIKV mutant unable to bind FHL1 (CHIKV-ΔFHL1) was avirulent and conferred protection against subsequent CHIKV/ONNV challenge.\",\n      \"method\": \"FHL1-/- mouse generation; in vivo infection with multiple alphaviruses; pull-down assays of nsP3 with FHL1; engineering of CHIKV-ΔFHL1 mutant; challenge experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO mouse model with multiple viral strains, direct pull-down confirming virus-specific binding, engineered viral mutant with in vivo functional validation; replicated across CHIKV and ONNV\",\n      \"pmids\": [\"37884534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The deubiquitinase OTUD1 deubiquitinates and stabilizes FHL1 protein, inhibiting lung adenocarcinoma progression. OTUD1 was identified as a FHL1-interacting protein by IP-MS, and co-IP confirmed their interaction; OTUD1 overexpression increased FHL1 protein levels without affecting FHL1 transcription.\",\n      \"method\": \"IP-MS identification of OTUD1 as FHL1 interactor; co-immunoprecipitation; western blot for FHL1 protein levels with OTUD1 manipulation; in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP-MS plus reciprocal Co-IP identifying deubiquitination interaction; functional protein stability assay; single lab\",\n      \"pmids\": [\"36929488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HOXD13 directly regulates FHL1 expression in rat embryo limb development. Luciferase assay and EMSA identified a novel FHL1 promoter region that directly interacts with HOXD13. Chromatin immunoprecipitation confirmed that endogenous HOXD13 interacts with this FHL1 promoter region in the developing limb.\",\n      \"method\": \"Luciferase reporter assay; EMSA; ChIP from developing rat limb; immunofluorescence staining of embryonic tissue\",\n      \"journal\": \"Cytogenetic and genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP from native tissue confirming endogenous HOXD13-FHL1 promoter interaction, supported by EMSA and luciferase assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18758158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FHL1 is a target of the cytotoxic protease granzyme B, indicating that generation of FHL1 fragments may initiate FHL1 autoimmunity in inflammatory myopathies (IIM). Anti-FHL1 autoantibodies were detected in 25% of IIM patients and were predictive for muscle atrophy and vasculitis.\",\n      \"method\": \"Granzyme B cleavage assay of FHL1; ELISA detection of anti-FHL1 autoantibodies in patient serum; immunization of myositis-prone mice with FHL1\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical granzyme B cleavage assay plus in vivo immunization model demonstrating pathogenic role; single lab\",\n      \"pmids\": [\"26551678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"5'RNA-Seq revealed that HCM induces altered transcriptional start-site usage of Fhl1, producing a distinct protein isoform in stressed myocytes. Genetic ablation of Fhl1 in HCM mice was deleterious, demonstrating that the stress-induced Fhl1 transcriptional change is salutary. This conserved response was also found in humans with genetic or acquired cardiomyopathies.\",\n      \"method\": \"5'RNA-Seq for genome-wide start-site usage; Fhl1 genetic ablation in HCM mouse model; isoform-specific protein detection; analysis of human HCM samples\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel RNA-seq methodology with genetic KO epistasis in HCM model; replicated in human samples; single lab\",\n      \"pmids\": [\"24509080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FHL1-/- mice subjected to left ventricular pressure overload showed a blunted hypertrophic response (confirming the published role of FHL1 in LV hypertrophy), but the same FHL1 deficiency did not diminish right ventricular hypertrophy, hypertrophic signaling, or dysfunction following pulmonary arterial banding, demonstrating that FHL1-mediated hypertrophic signaling is ventricle-specific.\",\n      \"method\": \"FHL1-/- mice; pulmonary arterial banding for RV pressure overload; echocardiography; gene expression analysis; comparison with transverse aortic constriction LV model\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse model with two pressure overload models (LV vs RV) as internal comparison; single lab; negative finding for RV is mechanistically informative\",\n      \"pmids\": [\"31980934\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FHL1 is a multi-isoform LIM domain scaffold protein predominantly expressed in skeletal and cardiac muscle that: (1) forms a sarcomeric complex sensing biomechanical stress via titin's N2B domain to activate MAPK-mediated hypertrophic signaling; (2) promotes skeletal muscle hypertrophy and myoblast differentiation by binding and activating the calcineurin/NFATc1 transcription factor axis; (3) undergoes Src-mediated phosphorylation at Y149/Y272 that switches its function from tumor suppressor (cytoplasmic, interacting with focal adhesion proteins including Kindlin-2 and Talin1) to oncogenic nuclear factor (binding BCLAF1); (4) interacts directly via its LIM1 domain with the hypervariable domain of chikungunya virus nsP3 to facilitate viral replication complex formation; and (5) produces isoforms (FHL1B/SLIMMER) that localize to the nuclear envelope and interact with RBP-J, Siva-1, lamin A/C, and emerin, with pathogenic missense mutations in the LIM2 or LIM4 domains causing protein aggregation, dominant-negative sequestration of NFATc1, and diverse X-linked myopathies.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FHL1 is a multi-isoform LIM-domain scaffold protein, predominantly expressed in striated muscle, that integrates biomechanical and growth-factor signals to control muscle gene expression, fiber differentiation, and stress hypertrophy [#0, #15]. In the cardiomyocyte sarcomere it forms a stretch-sensing complex with the titin N2B domain and MAPK components, acting downstream of Gq to drive pathological left-ventricular hypertrophy in a ventricle-specific manner [#0, #32]; it also assembles into a cytoskeletal complex with PDLIM1, gelsolin, and ACTN1 [#14]. A central effector function is its binding to and activation of the calcineurin/NFATc1 axis, which promotes skeletal-muscle hypertrophy, oxidative fiber-type switching, and—via an NFATc1–utrophin axis—can reassemble a substitute glycoprotein complex that ameliorates dystrophic pathology [#1, #19]. FHL1 expression is itself a signaling node, induced by Wnt/TCF-LEF and HOXD13 and downstream of Rho/CRIK, while its isoforms localize differentially to focal adhesions, actin filaments, the nucleus, and the nuclear envelope, where FHL1B associates with lamin A/C and emerin and FHL1B/SLIMMER binds the proapoptotic protein Siva-1 and RBP-J to repress Notch/EBNA2-dependent transcription [#2, #8, #18, #23, #26, #29, #16]. In cancer, FHL1 functions as a Src-regulated tumor suppressor: Src-Cas signaling silences FHL1 via promoter methylation, and Src phosphorylation at Y149/Y272 drives nuclear translocation and BCLAF1 binding, with Kindlin-2 and the deubiquitinase OTUD1 opposing this switch [#9, #11, #28]. FHL1 is also an essential host factor for chikungunya and O'nyong-nyong virus replication, binding the nsP3 hypervariable domain through its LIM1 domain [#5, #6, #27]. Pathogenic missense mutations in the LIM2/LIM4 domains cause dominant-negative protein aggregation that sequesters wild-type FHL1 and NFATc1, producing reducing body myopathy and related X-linked myopathies [#4, #22, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that FHL1 isoforms occupy distinct subcellular compartments, framing it as a protein whose function is partitioned between focal-adhesion signaling and nuclear-cytoplasmic communication.\",\n      \"evidence\": \"GFP-fusion live imaging and NLS/NES truncation analysis in COS-7 and myoblast/myotube cells\",\n      \"pmids\": [\"10480922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of each localization not defined\", \"Did not identify binding partners at focal adhesions or nucleus\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed isoform-specific nuclear targeting and tissue distribution (FHL1B brain-specific; FHL1C distributed via an RBP-J binding region), connecting FHL1 isoforms to transcriptional machinery.\",\n      \"evidence\": \"Isoform-specific immunoblot, subcellular fractionation, and tagged-isoform transfection\",\n      \"pmids\": [\"11400158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, antibody-based\", \"Functional role of RBP-J interaction not yet tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Linked FHL1 overexpression to integrin-dependent myocyte morphology, indicating a role in cell-shape and adhesion signaling during differentiation.\",\n      \"evidence\": \"Overexpression with alpha5beta1-integrin peptide blockade and substrate controls in myocytes\",\n      \"pmids\": [\"12917103\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of integrin engagement unresolved\", \"Overexpression-based; endogenous role untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed FHL1 (KyoT1/2) downstream of Rho/CRIK signaling as a suppressor of keratinocyte differentiation, extending its regulatory role beyond muscle.\",\n      \"evidence\": \"RhoA/CRIK manipulation and KyoT1/2 overexpression with differentiation assays in keratinocytes\",\n      \"pmids\": [\"16061799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FHL1 effector targets in keratinocytes unknown\", \"Single lab epistasis\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified FHL1 as a tumor suppressor whose silencing by promoter methylation is required for Src-driven transformation, defining the Src-Cas-FHL1 axis.\",\n      \"evidence\": \"Genome-wide expression analysis with Src/Cas manipulation and transformation assays in tumor cells\",\n      \"pmids\": [\"16452211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream tumor-suppressive effectors of FHL1 not identified here\", \"Correlative methylation link\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established FHL1 as a cardiac biomechanical stress sensor acting downstream of Gq, by tying it to titin N2B and MAPK signaling in hypertrophy.\",\n      \"evidence\": \"Fhl1 knockout mice with TAC, Gq transgenic epistasis, and Co-IP with titin N2B/MAPK components\",\n      \"pmids\": [\"19033658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise stretch-to-MAPK transduction step undefined\", \"Stoichiometry of the sarcomeric complex unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified FHL1 as the gene mutated in reducing body myopathy and showed mutants form dominant-negative aggregates, defining a gain-of-toxicity disease mechanism.\",\n      \"evidence\": \"Laser microdissection proteomics of inclusions plus mutant FHL1 transfection in COS-7/C2C12 cells\",\n      \"pmids\": [\"18274675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why specific LIM mutations aggregate not yet defined\", \"Spectrum of trapped proteins incomplete\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Refined the tumor-suppressor mechanism by showing Src promotes FHL1 promoter methylation independently of MAPK and that FHL1 induces Sdpr in tumors.\",\n      \"evidence\": \"Bisulfite sequencing, MAPK inhibitor epistasis, and tumor expression arrays/IHC\",\n      \"pmids\": [\"18422756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic link from Src/Cas to DNA methylation not shown\", \"Sdpr functional contribution untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Talin1 as an FHL1 partner in pulmonary artery smooth muscle and tied FHL1 to migration/proliferation in pulmonary hypertension.\",\n      \"evidence\": \"Proteomics, siRNA/overexpression, and Co-IP with Talin1 in primary human PASMCs\",\n      \"pmids\": [\"18725486\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional requirement of the Talin1 interaction not dissected\", \"Single disease context\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed KyoT3/FHL1 represses RBP-J-dependent transactivation, linking an FHL1 isoform to Notch/EBNA2 transcriptional control.\",\n      \"evidence\": \"EGFP localization, Co-IP with RBP-J, and luciferase reporter assays\",\n      \"pmids\": [\"18760388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context of Notch repression unclear\", \"Reporter-based functional readout\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated that HOXD13 directly binds the FHL1 promoter in developing limb, placing FHL1 in a developmental transcriptional program.\",\n      \"evidence\": \"Luciferase, EMSA, and ChIP from developing rat limb\",\n      \"pmids\": [\"18758158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of FHL1 in limb development not tested\", \"Single developmental system\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed SLIMMER/FHL1B binds the proapoptotic Siva-1 and delays apoptosis, assigning an isoform-specific survival function with dynamic localization across differentiation.\",\n      \"evidence\": \"Yeast two-hybrid, direct binding, GST pulldown from muscle, co-localization, and apoptosis assay in C2C12\",\n      \"pmids\": [\"19643733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FHL1B blocks Siva-1 apoptosis undefined\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified RIP140 as an FHL1 partner enhancing repression of estrogen-responsive transcription, extending FHL1 into nuclear-receptor corepression.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, reporter assays, and siRNA in mammalian cells\",\n      \"pmids\": [\"19401155\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether all FHL1 LIM domains directly contact RIP140 not structurally resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established the FHL1-NFATc1 axis as the core effector for skeletal muscle hypertrophy and showed disease mutants sequester NFATc1, unifying hypertrophic and myopathic mechanisms.\",\n      \"evidence\": \"Reciprocal Co-IP, calcineurin-inhibitor rescue in C2C12, NFATc1 localization, and FHL1 transgenic mice\",\n      \"pmids\": [\"19075112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical step by which FHL1 potentiates NFATc1 unclear\", \"Other calcineurin pathway nodes untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined FHL1 binding to the ER AF-1 domain and repression of estrogen-responsive promoters, broadening its corepressor role to estrogen receptor signaling.\",\n      \"evidence\": \"Co-IP, ChIP, reporter assays, and siRNA knockdown in breast cancer cells\",\n      \"pmids\": [\"19840196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship to FHL1-RIP140 corepression not integrated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a native FHL1 cytoskeletal complex (PDLIM1, gelsolin, ACTN1) in heart, supporting its scaffold function at the sarcomere.\",\n      \"evidence\": \"Tandem affinity purification-MS in HEK-293, reciprocal Co-IP in mouse heart, and 3D microscopy\",\n      \"pmids\": [\"21246116\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of each complex member with FHL1 not dissected\", \"Stoichiometry unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated FHL1A is required in vivo for muscle fiber differentiation/maturation and that loss causes age-dependent myopathy with autophagy upregulation.\",\n      \"evidence\": \"FHL1-null mice with histology/EM/function and isoform-specific FHL1A rescue in primary myoblasts\",\n      \"pmids\": [\"23975679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking FHL1 loss to autophagy increase undefined here\", \"Isoform-specific contributions only partially separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the FHL1-NFATc1 axis to drive utrophin expression and rescue dystrophic muscle, establishing a therapeutically relevant FHL1-NFATc1-utrophin pathway.\",\n      \"evidence\": \"FHL1 transgenic/mdx double-mutant mice, utrophin promoter reporter, and membrane stability/function assays\",\n      \"pmids\": [\"24087791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability and translatability of utrophin induction not addressed\", \"Direct NFATc1-utrophin promoter occupancy not fully mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed disease mutants segregate by phenotype—aggregation (RBM/SPM/XMPMA) versus reduced expression (HCM/EDMD)—and confirmed FHL1 acts through NFATc1 in differentiation via rescue.\",\n      \"evidence\": \"Disease-mutant expression in C2C12, Menadione-NBT staining, and constitutively active NFATc1 rescue\",\n      \"pmids\": [\"24634512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why mutation class dictates aggregation vs degradation unclear\", \"Cell-line based\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed that cardiac stress reprograms Fhl1 transcriptional start-site usage to produce a protective stress isoform, redefining FHL1 as an adaptive HCM response.\",\n      \"evidence\": \"5'RNA-Seq, Fhl1 ablation in HCM mice, isoform detection, and human cardiomyopathy samples\",\n      \"pmids\": [\"24509080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Function of the stress-specific isoform not biochemically defined\", \"Reconciliation with FHL1's pro-hypertrophic role needed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed FHL1 potentiates myostatin/TGFβ-SMAD signaling to promote muscle atrophy, revealing a context-dependent atrophic function opposing its hypertrophic role.\",\n      \"evidence\": \"SMAD reporter, myotube wasting, and in vivo FHL1/myostatin co-electroporation\",\n      \"pmids\": [\"26504741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular step by which FHL1 amplifies SMAD signaling unknown\", \"Reconciliation with pro-hypertrophic NFATc1 role unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified FHL1 as a granzyme B substrate and autoantigen in inflammatory myopathy, linking FHL1 fragmentation to muscle autoimmunity.\",\n      \"evidence\": \"Granzyme B cleavage assay, anti-FHL1 autoantibody ELISA in patients, and myositis-prone mouse immunization\",\n      \"pmids\": [\"26551678\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from cleavage to autoantibody generation incomplete\", \"Single lab patient cohort\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established FHL1 as a Wnt/TCF-LEF transcriptional target required for myotube formation, identifying an upstream regulator of FHL1 in myogenesis.\",\n      \"evidence\": \"Fhl1 promoter reporter, TCF/LEF site mutagenesis, β-catenin/LiCl treatment, and siRNA in C2C12\",\n      \"pmids\": [\"25676585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo Wnt-FHL1 dependence not tested\", \"Other myogenic inputs not compared\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Localized FHL1B to the nuclear envelope with lamin A/C and emerin and showed its dysregulation in EDMD patient myoblasts, connecting an FHL1 isoform to nuclear-envelope myopathy.\",\n      \"evidence\": \"Immunofluorescence, western blot, and fractionation in primary human and EDMD-patient myoblasts\",\n      \"pmids\": [\"27911330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of FHL1B at the nuclear envelope unresolved\", \"Whether FHL1B elevation is compensatory or pathogenic unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the phosphorylation switch converting FHL1 from cytoplasmic tumor suppressor to nuclear oncogenic factor, with Kindlin-2 antagonizing Src at focal adhesions.\",\n      \"evidence\": \"Src kinase assay, Y149/Y272 mutagenesis, Co-IP with BCLAF1 and Kindlin-2, fractionation, and proliferation assays\",\n      \"pmids\": [\"29434030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BCLAF1 target genes driving growth not identified\", \"Tissue contexts where switch operates limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked FHL1 to LC3 and autophagosome formation in myoblast differentiation and anti-atrophy regulation, integrating FHL1 into autophagy control.\",\n      \"evidence\": \"FHL1-LC3 Co-IP/co-IF and siRNA/overexpression with autophagy/atrophy marker readouts in chicken myoblasts\",\n      \"pmids\": [\"31637727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether FHL1-LC3 binding is direct unproven\", \"Cross-species generalization to mammalian muscle untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified FHL1 as an essential host factor for CHIKV replication through direct binding of the nsP3 hypervariable domain, establishing a proviral function.\",\n      \"evidence\": \"FHL1 KO/knockdown cells, direct binding, replication assays, re-expression rescue, and Fhl1-KO mice\",\n      \"pmids\": [\"31554973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic role of FHL1 in replication complex assembly undefined here\", \"Which LIM domain mediates binding not yet resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped the FHL1-nsP3 interaction to the LIM1 domain at a site overlapping CD2AP, providing structural resolution of the proviral interface.\",\n      \"evidence\": \"NMR structural mapping, LIM truncation analysis, and CHIKV replication/competition assays\",\n      \"pmids\": [\"33055253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether host LIM1 function is hijacked or merely scaffolds nsP3 unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed FHL1-mediated hypertrophic signaling is ventricle-specific, required for LV but dispensable for RV pressure-overload hypertrophy.\",\n      \"evidence\": \"FHL1-/- mice with pulmonary arterial banding versus aortic constriction and echocardiography\",\n      \"pmids\": [\"31980934\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis for ventricle-specific dependence unknown\", \"Compensating factors in RV not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a post-translational FHL1 mechanism promoting blastocyst-epithelial adhesion via HOXA10 stabilization through SIRT2-mediated deacetylation and downstream integrin/FAK activation.\",\n      \"evidence\": \"FHL1 overexpression/knockdown, mouse uterine knockdown, HOXA10-SIRT2 Co-IP, stability assays, and SIRT2 inhibitors\",\n      \"pmids\": [\"36418297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How FHL1 enhances HOXA10-SIRT2 binding not biochemically defined\", \"Single reproductive context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated virus-specific requirement for FHL1 in vivo (CHIKV/ONNV but not RRV/MAYV) and that a non-binding viral mutant is avirulent, validating FHL1 as a therapeutic and vaccine target.\",\n      \"evidence\": \"FHL1-/- mice infected with multiple alphaviruses, nsP3 pull-downs, and engineered CHIKV-ΔFHL1 challenge studies\",\n      \"pmids\": [\"37884534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why some alphavirus nsP3 fail to bind FHL1 unresolved\", \"Host signaling consequences of FHL1 hijacking unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified OTUD1 as a deubiquitinase that stabilizes FHL1 to restrain lung adenocarcinoma, adding post-translational control to FHL1's tumor-suppressor regulation.\",\n      \"evidence\": \"IP-MS, Co-IP, protein-level assays with OTUD1 manipulation, and in vitro/in vivo tumor growth\",\n      \"pmids\": [\"36929488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The opposing E3 ligase ubiquitinating FHL1 not identified\", \"Integration with Src-driven FHL1 silencing unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single LIM-domain scaffold reconciles opposing roles—pro-hypertrophic NFATc1 activation versus pro-atrophic myostatin amplification, tumor suppression versus phospho-driven oncogenesis—through isoform identity, post-translational modification, and partner selection remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking isoform/PTM state to functional output\", \"Structural basis of LIM-domain partner discrimination undefined\", \"Direct enzymatic activity, if any, of FHL1 unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [2, 3, 14]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 8, 12, 13, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 11, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 11, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 7, 8, 11, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 11]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [2, 3, 14]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 11, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [15, 19, 26, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 5, 27, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 12, 13, 19]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [0, 15, 32]}\n    ],\n    \"complexes\": [\n      \"FHL1-titin N2B sarcomeric stretch-sensor complex\",\n      \"FHL1-PDLIM1-gelsolin-ACTN1 cytoskeletal complex\"\n    ],\n    \"partners\": [\n      \"TTN\",\n      \"NFATc1\",\n      \"BCLAF1\",\n      \"FERMT2\",\n      \"TLN1\",\n      \"RBPJ\",\n      \"SIVA1\",\n      \"PDLIM1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}